FOLD240719P12000
- 2.40
- 0.000.00%
Amicus Therapeutics Newsroom
Stifel Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
Stifel analyst Dae Gon Ha maintains $Amicus Therapeutics(FOLD.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 37.0% and a to
Amicus Therapeutics(FOLD.US) Officer Sells US$14,002.94 in Common Stock
$Amicus Therapeutics(FOLD.US)$ Officer Campbell Bradley L sold 1,400 shares of common stock on Jul 1, 2024 at an average price of $10.0021 for a total value of $14,002.94.Source: Announcement What is
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Investors in Amicus Therapeutics (NASDAQ:FOLD) From a Year Ago Are Still Down 19%, Even After 3.9% Gain This Past Week
Amicus Therapeutics(FOLD.US) Officer Sells US$75,000 in Common Stock
$Amicus Therapeutics(FOLD.US)$ Officer Campbell Bradley L sold 7,500 shares of common stock on Jun 3, 2024 at an average price of $10 for a total value of $75,000.Source: Announcement What is statemen
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti (Cipaglucosidase Alfa) + Opfolda (Miglustat) as Best Pharmaceutical Product
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today
It's Unlikely That Shareholders Will Increase Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Compensation By Much This Year
Key Insights Amicus Therapeutics will host its Annual General Meeting on 6th of June CEO Brad Campbell's total compensation includes salary of US$698.6k Total compensation is similar to the indust
Amicus Therapeutics Inc: Wells Fargo launches insurance with an increase in holdings rating; target price is $18
Amicus Therapeutics Inc: Wells Fargo launches insurance with an increase in holdings rating; target price is $18
Express News | Amicus Therapeutics Inc : Wells Fargo Initiates Coverage With Overweight Rating; Target Price $18
Shareholders in Amicus Therapeutics (NASDAQ:FOLD) Are in the Red If They Invested Five Years Ago
Ideally, your overall portfolio should beat the market average. But even the best stock picker will only win with some selections. So we wouldn't blame long term Amicus Therapeutics, Inc. (NASDAQ:FO
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
6 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:FOLD) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below provides a snapsh
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Jefferies a
Guggenheim: Amicus Therapeutics (FOLD.US) rating was raised, adjusted from neutral to buy, with a target price of $13.00.
Guggenheim: Amicus Therapeutics (FOLD.US) rating was raised, adjusted from neutral to buy, with a target price of $13.00.
Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target
Amicus Therapeutics (FOLD) has an average outperform rating and a price target range of $13 to $21, according to analysts polled by Capital IQ. Price: 9.44, Change: +0.40, Percent Change: +4.42
Amicus Therapeutics Is Maintained at Buy by UBS
Amicus Therapeutics Is Maintained at Buy by UBS
UBS: Maintains Amicus Therapeutics (FOLD.US) rating, adjusted from buy to buy rating, and adjusted target price from $20.00 to $19.00.
UBS: Maintains Amicus Therapeutics (FOLD.US) rating, adjusted from buy to buy rating, and adjusted target price from $20.00 to $19.00.
UBS Maintains Buy on Amicus Therapeutics, Lowers Price Target to $19
UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and lowers the price target from $20 to $19.
Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...